Prime Medicine Inc
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
PRME$3.90-9.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows for the
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| Three Months EndedMarch 31, | ||
|---|---|---|
| (in thousands) | 2025 | 2024 |
| Cash flows used in operating activities: | ||
| Net loss | $(51,890) | $(45,761) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Stock-based compensation expense | 5,681 | 5,209 |
| Non cash lease expense | 2,413 | 3,348 |
| Depreciation expense | 1,700 | 1,315 |
| Change in fair value of short-term investment — related party | 1,056 | (1,166) |
| Amortization of premiums and discount on short-term investments | (164) | (675) |
| Deferred income taxes | — | 134 |
| Changes in operating assets and liabilities: | ||
| Collaboration receivable — related party | (17) | — |
| Prepaid expenses and other current assets | (789) | (2,794) |
| Accounts payable | 1,884 | (5,880) |
| Accrued expenses and other current liabilities | (6,655) | (4,475) |
| Accrued settlement payment — related party | — | (13,500) |
| Deferred revenue — related party | (1,438) | — |
| Lease liabilities | (638) | (3,462) |
| Net cash used in operating activities | (48,857) | (67,707) |
| Cash flows used in investing activities: | ||
| Maturities of investments | 3,000 | 72,500 |
| Purchases of investments | (48,320) | (107,208) |
| Purchases of property and equipment | (2,422) | (2,324) |
| Net cash used in investing activities | (47,742) | (37,032) |
| Cash flows provided by financing activities: | ||
| Proceeds from research and development funding liability | 6,000 | 6,000 |
| Proceeds from follow-on offering, net of issuance costs | — | 132,055 |
| Proceeds from issuance of pre-funded warrants, net of issuance costs | — | 18,800 |
| Proceeds from ESPP offerings | — | 436 |
| Net proceeds from stock option exercises | — | 36 |
| Net cash provided by financing activities | 6,000 | 157,327 |
| Net change in cash, cash equivalents, and restricted cash | (90,599) | 52,588 |
| Cash, cash equivalents, and restricted cash at beginning of period | 196,538 | 55,070 |
| Cash, cash equivalents, and restricted cash at end of period | $105,939 | $107,658 |
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| Three Months EndedMarch 31, | ||
|---|---|---|
| (in thousands) | 2025 | 2024 |
| Reconciliation of cash, cash equivalents and restricted cash: | ||
| Cash, cash equivalents, and restricted cash at end of period | $105,939 | $107,658 |
| Less: restricted cash | 14,062 | 13,496 |
| Total cash, and cash equivalents | $91,877 | $94,162 |
| Supplemental cash flow information: | ||
| Right-of-use assets obtained in exchange for new operating lease liabilities | $83,757 | $44,935 |
| Decrease in right-of-use assets due to lease termination | $3,120 | $— |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Purchases of property and equipment included in accounts payable and accrued expenses | $985 | $833 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.